Taken together, the mutational landscape of PGCA was defined by defects in cell-cycle regulation and immune response pathways, whereas the coexisting adenocarcinoma displayed abnormalities in metabolic signaling and p53-mediated apoptosis. Here, TP53 is linked to adenocarcinoma.